Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (21-30 of 169) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancerAndrea B Apolo, Jamie Riches, Heiko Schöder, et al.
Cancer|January 4, 2008
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumorAtreya Dash, Brett S Carver, Jason Stasi, et al.
World Journal of Urology|July 12, 2013
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancerPhilip H Kim, Matthew Kent, Philip Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinomaPadmanee Sharma, Yu Shen, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcomeAndrew J Stephenson, George J Bosl, Robert J Motzer, et al.
European Urology Oncology|November 12, 2020
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the BladderMathieu Rouanne, Dean F Bajorin, Raquibul Hannan, et al.
Journal of Oncology Practice|May 2, 2013
Who does not receive treatment for cancer?Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
International Journal of Surgical Pathology|April 3, 2002
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical featuresSatish K Tickoo, Brian Hutchinson, Jennifer Bacik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapyEllen A Ronnen, G Varuni Kondagunta, Jennifer Bacik, et al.
The Journal of Urology|August 21, 2015
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Pageof 17

Showing results (21-30 of 169) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2010
Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancerAndrea B Apolo, Jamie Riches, Heiko Schöder, et al.
Cancer|January 4, 2008
The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumorAtreya Dash, Brett S Carver, Jason Stasi, et al.
World Journal of Urology|July 12, 2013
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancerPhilip H Kim, Matthew Kent, Philip Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinomaPadmanee Sharma, Yu Shen, Sijin Wen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcomeAndrew J Stephenson, George J Bosl, Robert J Motzer, et al.
European Urology Oncology|November 12, 2020
Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the BladderMathieu Rouanne, Dean F Bajorin, Raquibul Hannan, et al.
Journal of Oncology Practice|May 2, 2013
Who does not receive treatment for cancer?Marcia M Ward, Fred Ullrich, Kevin Matthews, et al.
International Journal of Surgical Pathology|April 3, 2002
Testicular seminoma: a clinicopathologic and immunohistochemical study of 105 cases with special reference to seminomas with atypical featuresSatish K Tickoo, Brian Hutchinson, Jennifer Bacik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapyEllen A Ronnen, G Varuni Kondagunta, Jennifer Bacik, et al.
The Journal of Urology|August 21, 2015
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaGuru Sonpavde, Gregory R Pond, Jonathan E Rosenberg, et al.
Pageof 17